

86. A composition consisting essentially of, based on the total weight of the composition, β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

87. The composition of claim 86 consisting essentially of, based on the total weight of the composition, β -boswellic acid of at least 14% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 55% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

88. The composition of claim 86 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

89. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 12 to 30% by weight, acetyl- β -boswellic acid of 10 to 25% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

90. The composition of claim 89 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 30% by weight, acetyl- β -boswellic acid of 10 to 20% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

91. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 35% by weight, acetyl- β -boswellic acid of 10 to 20%

by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

92. The composition of claim 88 consisting essentially of, based on the total weight of the composition, β -boswellic acid of 14 to 35% by weight, acetyl- β -boswellic acid of 10 to 20% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

93. The composition of claim 86, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

94. A composition comprising three boswellic acids selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is at least 5% by weight, the amount of acetyl- β -boswellic acid is at least 5% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

95. The composition of claim 94, wherein the amount of β -boswellic acid is 14 to 65% by weight, the amount of acetyl- β -boswellic acid is 5 to 65% by weight, the amount of 11-keto- β -boswellic acid is 15 to 60% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 60% by weight.

96. The composition of claim 95, wherein the amount of β -boswellic acid is 14 to 55% by weight, the amount of acetyl- β -boswellic acid is 10 to 55% by weight, the amount of 11-keto- β -boswellic acid is 15 to 50% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 50% by weight.

97. The composition of claim 96, wherein the amount of β -boswellic acid is 14 to 35% by weight, the amount of acetyl- β -boswellic acid is 10 to 35% by weight, the amount of 11-keto- β -boswellic acid is 15 to 40% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 40% by weight.

98. The composition of claim 94, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

99. A composition comprising two boswellic acids selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is 1 to 34% or at least 56% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or at least 46% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

100. The composition of claim 99, wherein the amount of β -boswellic acid is 1 to 34% or 56 to 95% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 46 to 95% by weight, the amount of 11-keto- β -boswellic acid is 15 to 95% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 95% by weight.

101. The composition of claim 100, wherein the amount of β -boswellic acid is 1 to 34% or 56 to 70% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 46 to 70% by weight, the amount of 11-keto- β -boswellic acid is 30 to 70% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 30 to 70% by weight.

102. The composition of claim 101, wherein the amount of β -boswellic acid is 1 to 34% or 40 to 60% by weight, the amount of acetyl- β -boswellic acid is 1 to 24% or 40 to 60% by weight, the amount of 11-keto- β -boswellic acid is 40 to 60% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 40 to 60% by weight.

103. The composition of claim 99, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

104. A composition comprising boswellic acids, wherein the boswellic acids consist of three substances selected from the group consisting of β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid, wherein, based on the total weight of the composition, the amount of β -boswellic acid is at least 5% by weight, the amount of acetyl- β -boswellic acid is at least 5% by weight, the amount of 11-keto- β -boswellic acid is at least 15% by weight, and the amount of acetyl-11-keto- β -boswellic acid is at least 14% by weight.

105. The composition of claim 104, wherein the amount of β -boswellic acid is 5 to 65% by weight, the amount of acetyl- β -boswellic acid is 5 to 65% by weight, the amount of 11-keto- β -boswellic acid is 15 to 65% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 14 to 65% by weight.

106. The composition of claim 105, wherein the amount of β -boswellic acid is 15 to 55% by weight, the amount of acetyl- β -boswellic acid is 15 to 55% by weight, the amount of 11-keto- β -boswellic acid is 15 to 55% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 15 to 55% by weight.

107. The composition of claim 106, wherein the amount of β -boswellic acid is 20 to 40% by weight, the amount of acetyl- β -boswellic acid is 20 to 40% by weight, the amount of 11-keto- β -boswellic acid is 20 to 40% by weight, and the amount of acetyl-11-keto- β -boswellic acid is 20 to 40% by weight.

108. The composition of claim 104, wherein the β -boswellic acid, acetyl- β -boswellic acid, 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid are derived from any natural source.

114. The composition of claim 94, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

5 115. The composition of claim 94, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

116. The composition of claim 96, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

10 117. The composition of claim 97, wherein two of the three boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

M 118. The composition of claim 99, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

15 119. The composition of claim 100, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

20 120. The composition of claim 101, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

121. The composition of claim 102, wherein the two boswellic acids are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

25 122. The composition of claim 104, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

30 123. The composition of claim 105, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

124. The composition of claim 106, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

125. The composition of claim 107, wherein two of the three substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

126. The composition of claim 109, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

127. The composition of claim 110, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

128. The composition of claim 111, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

129. The composition of claim 112, wherein the two substances are 11-keto- β -boswellic acid and acetyl-11-keto- β -boswellic acid.

130. A method for inhibition of DNA, RNA and/or protein synthesis in a human or animal in need of the inhibition, comprising a step of administering a DNA, RNA and/or protein synthesis inhibition effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

131. The method of claim 130, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

132. The method of claim 131, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

5 133. A method for irreversible inhibition of DNA synthesis in a human or animal in need of the inhibition, comprising a step of administering a DNA inhibition effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

10 134. The method of claim 133, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

15 135. The method of claim 134, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

20 136. A method for the prevention of a lymphoproliferative disease in a human or animal in need of the prevention, comprising a step of administering a lymphoproliferative disease prevention effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

25 137. The method of claim 136, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

138. The method of claim 137, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

5 139. The method of claim 136, wherein the lymphoproliferative disease is leukemia or lymphoma.

10 140. A method for the treatment of a lymphoproliferative disease in a human or animal in need of the treatment, comprising a step of administering a lymphoproliferative disease treatment effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

15 141. The method of claim 140, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

20 142. The method of claim 141, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

143. The method of claim 140, wherein the lymphoproliferative disease is leukemia or lymphoma.

25 144. A method for the prevention of an autoimmune disease in a human or animal in need of the prevention, comprising a step of administering an autoimmune disease prevention effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by

weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

145. The method of claim 144, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

146. The method of claim 145, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

147. The method of claim 144, wherein the autoimmune disease is psoriasis, sarcoidosis, systemic lupus erythematosus, Grave's disease, Hashimoto's thyroiditis, silent thyroiditis, Crohn's disease, Goodpasture syndrome, insulin-dependent diabetes mellitus, insulin-resistant diabetes mellitus, myasthenia gravis, Addison's disease, idiopathic hypoparathyroidism, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, rheumatoid arthritis or scleroderma.

148. A method for the treatment of an autoimmune disease in a human or animal in need of the treatment, comprising a step of administering an autoimmune disease treatment effective amount of a composition to said human or animal, wherein the composition comprises β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

149. The method of claim 148, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

157. The method of claim 156, wherein the composition comprises β -boswellic acid of at least 12% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight and acetyl-11-keto- β -boswellic acid of at least 14% by weight.

158. The method of claim 157, wherein the composition comprises β -boswellic acid of 12 to 35% by weight, acetyl- β -boswellic acid of 5 to 35% by weight, 11-keto- β -boswellic acid of 15 to 45% by weight and acetyl-11-keto- β -boswellic acid of 14 to 45% by weight.

159. A method of inhibiting the synthesis of DNA, RNA and/or protein in a human or animal in need of the inhibition, comprising administering a DNA, RNA and/or protein synthesis inhibition effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

160. A method for irreversibly inhibiting the synthesis of DNA in a human or animal in need of the inhibition, comprising administering a DNA synthesis inhibition effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

161. A method for preventing or treating a lymphoproliferative disease in a human or animal in need of the prevention or treatment, comprising administering a lymphoproliferative disease preventing or treating effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

26/13

AI 162. A method for preventing or treating an autoimmune disease in a human or animal in need of the prevention or treatment, comprising administering an autoimmune disease preventing or treating effective amount of β -boswellic acid of at least 5% by weight, acetyl- β -boswellic acid of at least 5% by weight, 11-keto- β -boswellic acid of at least 15% by weight
5 or acetyl-11-keto- β -boswellic acid of at least 14% by weight.

163. A composition comprising 11-keto- β -boswellic acid in an amount of at least 5% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 5% by weight.
164. A composition comprising 11-keto- β -boswellic acid in an amount of at least 30% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 30% by weight.
165. A composition comprising 11-keto- β -boswellic acid in an amount of 100% by weight which is the equivalent of 11-keto- β -boswellic acid in an amount of at least 95% by weight and acetyl-11-keto- β -boswellic acid in an amount of at least 5% by weight.
166. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising 11-keto- β -boswellic acid.
167. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising acetyl-11-keto- β -boswellic acid.
168. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising β -boswellic acid.
169. A composition suitable for treating inflammatory, lymphoproliferative and autoimmune conditions comprising acetyl- β -boswellic acid.
170. A method for inhibition of DNA, RNA and/or protein synthesis in a human or animal in need of the inhibition, comprising administering a DNA, RNA and/or protein synthesis inhibition effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.
171. A method for irreversible inhibition of DNA synthesis in a human or animal in need of the inhibition, comprising administering a DNA inhibition effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

172: ~~A method for the prevention of a lymphoproliferative disease in a human or animal in need of the prevention, comprising administering a lymphoproliferative disease prevention effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.~~

5

173. A method for the treatment of a lymphoproliferative disease in a human or animal in need of the treatment, comprising administering a lymphoproliferative disease treatment effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

10

174. A method for the prevention of an autoimmune disease in a human or animal in need of the prevention, comprising administering an autoimmune disease prevention effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

15

175. A method for the treatment of an autoimmune disease in a human or animal in need of the treatment, comprising administering an autoimmune disease treatment effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.

20

176. A method for the treatment of a tumor in a human or animal in need of the treatment, comprising administering a tumor treating effective amount of a composition to said human or animal, wherein the composition comprises acetyl-11-keto- β -boswellic acid.